Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

Here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker's has reported since April 22: ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

Wall Street has officially closed the books on April and now steps into May with cautious optimism. After a turbulent start ...

Gilead held dinners to promote its HIV medications at expensive restaurants that federal authorities claim were “wholly inappropriate” venues, Stat reported. Gilead said it settled to avoid the cost ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...